Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Fewer hours. Same pay. Possible approach to the Economic Singularity?

In 2019, Iceland made headlines by becoming one of the first countries in the to adopt the four-day working week, not through a general law, but through agreements allowing workers to negotiate shorter weeks or reduced hours. Five years on, the results are indisputable.

The Icelandic experiment began in 2015 with a pilot phase involving around 2,500 employees, or just over 1% of the country’s working population. Following the resounding success of this initiative, with 86% of the employees involved expressing their support, the project was formalised in 2019. Today, almost 90% of Icelandic workers benefit from a reduced working week of 36 hours, compared with 40 hours previously, with no loss of pay.

Initial concerns about the four-day week were widespread, both in Iceland and elsewhere in the world. There were fears of a drop in productivity, increased costs for businesses and difficulties in adapting to maintain service levels. However, the Icelandic experience has swept these fears under the carpet.

Read more | >

The moon’s nearside (that is, the side facing Earth) is dark-colored and dominated by ancient lava flows, whereas the farside is more rugged—and NASA researchers now suggest it’s due to a wonky lunar interior. Using data from twin spacecraft named Ebb and Flow, they found a 2–3% difference in the moon mantle’s ability to deform on each side. They say this data could be explained by the nearest hemisphere’s insides being up to 170°C hotter than the farside.

The detection of differences between the moon’s interior in the near and far hemispheres is reported in Nature this week.

Read more | >

The United States on Friday approved the first blood test for Alzheimer’s, a move that could help patients begin treatment earlier with newly approved drugs that slow the progression of the devastating neurological disease.

The test, developed by Fujirebio Diagnostics, measures the ratio of two proteins in the blood. The ratio is correlated with amyloid plaques in the brain—a hallmark of Alzheimer’s that, until now, has been detected only through brain scans or spinal fluid analysis.

“Alzheimer’s disease impacts too many people—more than breast cancer and prostate cancer combined,” said Food and Drug Administration Commissioner Marty Makary.

Read more | >

In patients with an advanced type of skin cancer called cutaneous squamous cell carcinoma (cSCC), those who received the combination of the immunotherapy drug avelumab and targeted agent cetuximab had almost four times longer median progression-free survival compared to patients who received avelumab alone, according to the results of a phase 2 trial presented today at the American Society of Clinical Oncology (ASCO) meeting and concurrently published in the Journal of Clinical Oncology.

“It is both an honor and humbling to develop clinical trials that can be potential options for our patients,” said lead author and study chair for the trial, Dan Zandberg, M.D., associate professor of medicine at the University of Pittsburgh and medical oncology co-leader of the head and neck cancer program at UPMC Hillman Cancer Center. “My hope is that the insights we made with this trial will lead to additional studies that can ultimately bring a new immunotherapy-based combination into standard of care for patients with advanced cSCC.”

CSCC is a common type of skin cancer with about 1.8 million cases diagnosed in the U.S. each year. About 95% of cSCCs are detected early and can be treated with minor surgery. But in rare cases, patients will go on to develop advanced cSCC, which includes locally advanced tumors that cannot be surgically removed and metastatic disease. At this point, the prognosis is poor and treatment is focused on extending survival, not cure.

Read more | >

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell therapy in nearly two-thirds of patients.

While survival data is still accumulating, several patients lived 12 months or longer after receiving the investigational therapy, which is notable given the typical survival for this patient population is less than a year.

The findings were presented at the 2025 American Society of Clinical Oncology (ASCO) annual meeting (Abstract 102) and published in Nature Medicine by researchers from the Abramson Cancer Center (ACC) of the University of Pennsylvania and Penn’s Perelman School of Medicine.

Read more | >

Join us on Patreon! https://www.patreon.com/MichaelLustgartenPhD

Discount Links/Affiliates:
Blood testing (where I get the majority of my labs): https://www.ultalabtests.com/partners/michaellustgarten.

At-Home Metabolomics: https://www.iollo.com?ref=michael-lustgarten.
Use Code: CONQUERAGING At Checkout.

Clearly Filtered Water Filter: https://get.aspr.app/SHoPY

Epigenetic, Telomere Testing: https://trudiagnostic.com/?irclickid=U-s3Ii2r7xyIU-LSYLyQdQ6…M0&irgwc=1
Use Code: CONQUERAGING

NAD+ Quantification: https://www.jinfiniti.com/intracellular-nad-test/

Continue reading “Supplements, Diet That Correspond To A 17y Younger Biological Age (Test #3 in 2025)” | >